ID   SaOS-LM7
AC   CVCL_0515
SY   SAOS-LM7; Saos-LM7; SaOs-lm7; SaOS/LM7; LM7
DR   MCCL; MCC:0000413
DR   GEO; GSM1914992
DR   GEO; GSM1914993
DR   GEO; GSM1914994
DR   GEO; GSM1914995
DR   Wikidata; Q54952110
RX   PubMed=22075555;
RX   PubMed=22186140;
RX   PubMed=24136885;
RX   PubMed=26320182;
RX   PubMed=29334376;
CC   Population: Caucasian.
CC   Characteristics: Metastatic. Established by 7 cycling of parent cell line through the lungs of nude mice.
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Bone; UBERON=UBERON_0002481.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9568 ! SaOS-LM6
SX   Female
AG   11Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 16
//
RX   PubMed=22075555; DOI=10.1158/0008-5472.CAN-11-2778; PMCID=PMC3833671;
RA   Huang G.-X., Yu L., Cooper L.J.N., Hollomon M., Huls H., Kleinerman E.S.;
RT   "Genetically modified T cells targeting interleukin-11 receptor
RT   alpha-chain kill human osteosarcoma cells and induce the regression of
RT   established osteosarcoma lung metastases.";
RL   Cancer Res. 72:271-281(2012).
//
RX   PubMed=22186140; DOI=10.1158/0008-5472.CAN-11-1460; PMCID=PMC3288434;
RA   Huang G.-X., Nishimoto K., Zhou Z.-C., Hughes D.P.M., Kleinerman E.S.;
RT   "miR-20a encoded by the miR-17-92 cluster increases the metastatic
RT   potential of osteosarcoma cells by regulating Fas expression.";
RL   Cancer Res. 72:908-916(2012).
//
RX   PubMed=24136885; DOI=10.1002/pbc.24801; PMCID=PMC4154381;
RA   Guma S.R., Lee D.A., Yu L., Gordon N., Hughes D., Stewart J.,
RA   Wang W.-L., Kleinerman E.S.;
RT   "Natural killer cell therapy and aerosol interleukin-2 for the
RT   treatment of osteosarcoma lung metastasis.";
RL   Pediatr. Blood Cancer 61:618-626(2014).
//
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177; PMCID=PMC4745740;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q.,
RA   Luu H.H., Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).
//
RX   PubMed=29334376; DOI=10.1038/nm.4475; PMCID=PMC5803371;
RA   Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A.,
RA   Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A.,
RA   Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A.,
RA   DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P.,
RA   Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.;
RT   "Positively selected enhancer elements endow osteosarcoma cells with
RT   metastatic competence.";
RL   Nat. Med. 24:176-185(2018).
//